Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 06, 2019 09:00 ET | Source: Aptevo Therapeutics Inc.

Aptevo Therapeutics Receives Orphan Drug Designation for APVO436 for the Treatment of Acute Myelogenous Leukemia

SEATTLE, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that the...
November 08, 2019 09:00 ET | Source: Aptevo Therapeutics Inc.

Aptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting

Preclinical Data Show That ALG.APV-527 is Well Tolerated with Repeated Dosing Preliminary in vivo Data Show that ALG.APV-527 has Potent Anti-tumor Activity and Induces an Immunological Memory...
November 07, 2019 09:00 ET | Source: Aptevo Therapeutics Inc.

Aptevo Therapeutics Reports Third Quarter 2019 Financial Results

Reports Record Net Revenue for IXINITY; Achieves 55% Increase in Year-over-Year Quarterly Net Revenue Advances APVO436 Phase 1/1b Clinical Study in AML/MDS SEATTLE, Nov. 07, 2019 (GLOBE NEWSWIRE)...
October 03, 2019 16:02 ET | Source: Aptevo Therapeutics Inc.

Aptevo Therapeutics Provides Corporate and Pipeline Update

Reports Record Quarterly IXINITY® Net Revenue and New Patient Conversions Following Launch of New 3,000 IU Assay Provides Update on Ongoing APVO436 Phase 1/1b Clinical Study;Evidence of Potential...
September 19, 2019 09:00 ET | Source: Aptevo Therapeutics Inc.

Aptevo Therapeutics Introduces New Adaptir™ Bispecific Antibody Candidate Intended for the Treatment of Solid Tumors

New ADAPTIR Candidate APVO603 is a Dual-Agonistic BispecificAntibody Targeting 4-1BB and OX40 APVO603 is Designed to Induce Synergistic Effects on Immune Responseswith Potential to Enhance...
August 09, 2019 09:00 ET | Source: Aptevo Therapeutics Inc.

Aptevo Therapeutics Reports Second Quarter 2019 Financial Results

Reports Positive Preliminary Top-Line Safety Data for APVO210Phase 1 Single Ascending Dose (SAD) Clinical Study Advances APVO210 into Phase 1 Multiple Ascending Dose (MAD) Study Commences Dosing...
August 07, 2019 09:02 ET | Source: Aptevo Therapeutics Inc.

Aptevo Therapeutics Receives $4.3 Million Milestone Payment From Saol International Limited

SEATTLE, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today the...
July 25, 2019 16:32 ET | Source: Aptevo Therapeutics Inc.

Aptevo Therapeutics Reports Continued Progress In APVO210 and APVO436 Clinical Trials

Completes Dosing in Single Ascending Dose (SAD) Phase 1 Study of APVO210 Receives Approval to Begin APVO210 Multiple Ascending Dose (MAD) Study Preliminary Data Suggest that Single Doses of APVO210...
June 25, 2019 09:00 ET | Source: Aptevo Therapeutics Inc.

Aptevo Therapeutics Launches New 3000 IU IXINITY Assay Offering Enhanced User Experience and Improved Convenience for Hemophilia B Patients

Expands Options for Patients with Potential for Reduced Reconstitution Time and Infusion Volume SEATTLE, June 25, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a...
May 09, 2019 09:00 ET | Source: Aptevo Therapeutics Inc.

Aptevo Therapeutics Reports First Quarter 2019 Financial Results

Achieves 73% Increase in First Quarter 2019 Year-Over-Year IXINITY® Net Revenue On Target for Launch of New 3,000 IU IXINITY Assay Mid-2019 Advances Enrollment in APVO436 and APVO210 Phase 1...